Abstract

BackgroundUmbilical cord blood provides a source of hematopoietic stem cells for transplantation with immunological and availability advantages over conventional bone marrow sources. Limited cell numbers and slower engraftment from umbilical cord blood units has led to the clinical development of immobilised Notch ligand Delta-Like 1 to promote ex vivo expansion of a rapidly engrafting cell population. However, current immobilisation methods are not simple to scale in a controlled manner.ResultsDelta-Like 1 was immobilised onto streptavidin coated magnetic particles via a heterobifunctionalised polyethylene glycol linker molecule to provide an easily manipulated format of surface protein presentation. CD34+ enriched cord blood cells were treated with Delta-Like 1 immobilised particles, and immunophenotypic markers measured to monitor population distributions using cluster identification, characterization, and regression software. The amenability of the approach to scalability was evaluated in a micro-scale stirred tank bioreactor. Surface concentration of Delta-Like 1 was well controlled used differing stoichiometric reagent ratios. Protein immobilisation was a cost effective process and particles were efficiently removed from the final cell product. Immobilised Delta-Like 1 is functional and stimulates qualitatively similar CD34hi, CD38lo, CD90lo, CD133hi, CD135hi progenitor expansion in both static culture and scalable stirred culture platforms.ConclusionsImmobilised Delta-Like 1 in this form has the potential to improve the manufacturing efficiency and control of final ex vivo expanded cell product through compatibility with highly controlled and characterised suspension culture systems.

Highlights

  • Umbilical cord blood provides a source of hematopoietic stem cells for transplantation with immunological and availability advantages over conventional bone marrow sources

  • Hematopoietic stem cell (HSC) are available from various human sources: mobilised peripheral blood (MPB), bone marrow (BM), and umbilical cord blood (UCB)

  • Optimal conditions for the immobilisation of Delta-like 1 The synthesis of an immobilised ligand complex using streptavidin/biotin interactions can take place via two discreet pathways: attaching the heterobifunctionalised polyethylene glycol (PEG) molecule to the protein followed by incubation with the particle, or attaching the heterobifunctionalised PEG molecule to the streptavidin particle followed by incubation with the protein (Fig. 1a)

Read more

Summary

Introduction

Umbilical cord blood provides a source of hematopoietic stem cells for transplantation with immunological and availability advantages over conventional bone marrow sources. Hematopoietic stem cell (HSC) transplantation is an effective therapy for numerous hematopoietic disorders. HSCs are available from various human sources: mobilised peripheral blood (MPB), bone marrow (BM), and umbilical cord blood (UCB). All have shown clinical efficacy, HSCs derived from UCB eliminates risk to the donor, are readily available as a sustainable source, offer a lower transmission rate of infectious and genetic diseases, and are more tolerant of immunological mismatches compared to those from other sources [1]. One of the key drawbacks of UCB as a source is the inability to obtain sufficient numbers of HSCs from a single cord for transplantation into the

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call